Redhill Biopharma Ltd (RDHL) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access RDHL Annual Income Statement →
The income statement data below highlights shifts in Redhill Biopharma Ltd's operating performance over recent quarters.
Quarterly Report, GAAP in USD millions
ITEM
(Dec 31 2025)
Q4 2025
0 0 0 (Dec 31 2024)
Revenues
Total Revenue0.29
Costs & Expenses
Cost of Goods and Services Sold0.00
Gross Profit0.29
Selling, Administration, Marketing6.17
Research and Development Expense2.02
OtherOperating Income Expense0.03
Total operating costs including COS8.23
Operating income / -loss-7.94
Net Interest (-)Expense / Income0.00
Other loss / -income-2.64
Total costs & expenses8.37
Income & Taxes
Income / -loss before income taxes-8.08
Income after income taxes-0.43
Net income / -loss of other equity7.65
Income / -loss from continuing operations-0.43
Net income / -loss-0.43
Income / -loss to shareholder-0.43
EBIT-8.08
EBITD-7.70
EBITDA-7.67
Earnings Per Share
Basic EPS (excl. extra items)0.00
Basic Net EPS0.00
Diluted Net EPS0.00
4 historic quarters locked

Sign in to unlock the full Redhill Biopharma Ltd income statement history.

About RDHL Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.